Dae Ho Lee

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021 · 253 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

Changhwan Sung, Jinhyeon An, Jaesoon Park et al. · Nature Cancer · 2023 · 48 citations

Life Sciences, Immunology, Oncology +17

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma

Omid Hamid, Karl D. Lewis, Amy Weise et al. · Journal of Clinical Oncology · 2024 · 39 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

Dong-Won Kang, Sun‐Kyeong Park, Yiyang Yu et al. · ESMO Open · 2024 · 14 citations · Full text

Medicine, Molecular Medicine, Oncology +11